Sycomore Francecap

Sycomore Francecap seeks to beat the French equity market by outperforming the CAC All-Tradable NR index over the long term. The investment universe comprises all listed French stocks with no sector, style or size constraints. Depending on the fund manager’s expectations, a large part of the portfolio may be invested in mid cap stocks.

Les labels permettent l’identification de placements responsables et durables pour les épargnants. Ils visent à guider les investisseurs mais n’offrent pas de garantie du capital investi et n’attestent pas de la qualité de la gestion mise en œuvre au travers des fonds. Pour un résumé des droits de l’investisseur et des directives relatives à une action individuelle ou collective, nous vous invitons à consulter le prospectus du fonds et son document d’information clé pour l’investisseur, ainsi que la politique de traitement des réclamations et plaintes de Sycomore AM. Sycomore AM peut décider de cesser la commercialisation de ses organismes de placement collectifs conformément à l’art. 93 bis de la directive 2009/65/CE et à l’article 32 bis de la directive 2011/61/UE.

L’indicateur synthétique de risque permet d’apprécier le niveau de risque de ce produit par rapport à d’autres. Il indique la probabilité que ce produit enregistre des pertes en cas de mouvements sur les marchés ou d'une impossibilité de notrepart de vous payer. Nous avons classé le produit dans la classe de risque 5 sur 7, qui est une classe de risque moyen à élevé. Cela évalue les pertes potentielles de performances futures à un niveau moyen élevé, et les mauvaises conditions du marché auront probablement un impact sur notre capacité à vous payer.

After a strong earnings season in October, the market rose in November as inflation readings hit an inflection point in the US. Declining interest rates enabled growth stocks to deliver robust returns. As a result, Believe, Soitec, STMicroelectronics, Schneider Electric and Christian Dior featured among the fund’s top contributors. Leading detractors in November included Sanofi and Boiron, which suffered from their defensive profiles despite reporting decent earnings. Chargeurs and Nexans fell sharply during the month. Nexans suffered from profit taking as the stock price remains close to its record highs. Chargeurs published subdued earnings in Q3 as the company’s “protective films” division declined by 16% (organic).

We would like to draw investors’ attention to the fact that the information available on this website is of a general nature and should not be construed as either adapted to the specific needs or circumstances of a given investor, nor as providing personal investment recommendations or financial advice.

The information available on this website is provided for information purposes only. SYCOMORE ASSET MANAGEMENT cannot be held liable for an investment or divestment decision made solely on the basis of the information provided herein. Although we believe the information made available on this website to be reliable, it should not be assumed to be exhaustive. SYCOMORE AM reserves the right to amend the contents on a discretionary basis and with no prior notice. If, despite the attention paid by SYCOMORE AM to the quality and timeliness of the information published on this website, some of the information is proved to be wrong or incomplete, SYCOMORE AM shall correct the situation as soon as possible but cannot be held liable for any errors, omissions or flaws that may be noted. Where necessary, you may report any flaws you have noted at the following address: info@sycomore-am.com.

We would like to remind investors that past performance is no guide to future returns and is not consistent over time. Our funds offer no yield or performance guarantees and carry a risk of capital loss. Before investing, please read the fund’s KIID available on our website www.sycomore-am.com or upon simple request from SYCOMORE ASSET MANAGEMENT. Our funds are offered to all investors and may be used in unit-based life-assurance contracts. The minimum investment horizon of each fund is indicated in its prospectus. The amount that is reasonable to invest in our funds will depend upon your personal situation. This can be determined by considering your personal wealth, current and future needs, and whether you are prepared to take on risks or prefer a cautious investment. We also highly recommend that you diversify your investments sufficiently to avoid exposing your capital exclusively to the risks associated with our funds.

The funds presented below are domiciled in France or in Luxembourg and may not be authorized for sale in your country. Each fund factsheet provides information on the countries in which the fund is registered. Units of our FCPs – which are Foreign Public Funds as per section 13 of the US Bank Holding Company Act – have not been registered or declared to the US authorities as per the US Securities Act of 1933. As a result, they may not be offered or sold, either directly or indirectly, in the United States or on behalf of a “US Person” as defined by the US regulation (Regulation S). In all circumstances, the user of the present site is responsible for ensuring beforehand that his or her connection to this website and access to the information contained herein is neither a failure to meet regulatory obligations, nor a regulatory violation on account of his or her own legal situation, particularly with respect to the national law applicable to the individual.

Track record

Cyril Charlot

Hadrien Bulté

Anne-Claire Imperiale

Performance as of 11.19.2024

Characteristics

Classification

Subscriptions & redemptions

Management fees

Risk indicator

Looking to invest?

Find out more

Contact us

Non-liability clause